Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ)
Beijing, CN
Beijing Science Sun Pharmaceutical Co., Ltd. is a company, established in 1999 and headquartered in Beijing, China, that operates within the Chinese pharmaceutical market. It is dedicated to the research, development, manufacturing, and distribution of injectable medications. The firm offers a wide array of products designed to treat conditions related to the cardiovascular, cerebrovascular, immunomodulatory, and nervous systems, among other health areas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.95% | -2.63% | -18.42% | -21.65% | -24.45% | -15.88% | -15.48% | -16.59% | -34.99% | -60.27% | -35.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.8% Q1'26: -2.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+121.4% ★ Q1'26: -88.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.5% Q1'26: +8.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.2% Q1'26: +10.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.4% Q1'26: +1.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.33× ★ Q1'26: 0.52× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
|---|---|
| Revenue |
1.43B
est: 787.50M (+81.3%)
|
| EBITDA |
354.51M
est: 137.63M (+157.6%)
|
| EBIT |
331.76M
est: 79.78M (+315.8%)
|
| Net Income |
283.11M
|
| SGA |
884.90M
est: 407.47M (+117.2%)
|
| EPS |
0.59
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 2/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 154.9K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 93.4K | 0.29% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 11.6K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.1K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 572.2K | 0.06% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 489.9K | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 919.40 | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.8K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.5K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 655.90 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Biao Ma | Chairman & GM | — | male |
| Dongna Liang | Financial Director | — | female |
| Li Ma | Deputy GM & Director | — | female |
| Shen Yinfu | Marketing Director | — | male |
| Shuangquan Kong | Chief Engineer | — | male |
| Xue Feng Wang | Deputy GM, Secretary of the Board & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300485.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
